Introduction
Telomeres consist of several thousands (TTAGGG in humans) n of nucleotide repeats and a protein complex at the ends of chromosomes, maintaining genomic stability by protecting chromosomes from degradation, end-to-end fusion, and recombination (1). Human telomeres, as a marker for biological age, are approximately 10-15 kb in somatic cells and progressively shortened with each cell division. Age-dependent shortening of telomeres impairs function and viability of human cells, and both very short and very long telomeres promote carcinogenesis (2, 3), also a recognized marker carcinogenesis.
TERT encodes the reverse transcriptase component of the telomerase, necessary for the maintenance of telomere length, chromosomal stability, and cellular immortality. Normally, TERT mRNA is not expressed in most human somatic cells; however, abnormal expression of TERT mRNA and protein occurs in many cancer types, including head and neck cancer.
Recently, genome-wide association studies have reported associations between TERT genotypes and risk of several cancer types (4, 5) , but few studies investigated the correlation among TERT genotypes, telomere length, and cancer risk. A recent study showed that TERT-CLPTM1L variants were associated with both of the mean relative telomere length (RTL) and cancer risk (4), but another study reported no association of the TERT-CLPTM1L rs401681 SNP with RTL or cancer risk, including breast cancer, colorectal cancer and melanoma (6) . One study of the FISH-measured TRL suggested a shorter RTL in head and neck cancer but the related risk was not estimated (2) , and no study has investigated associations among TERT genotypes, RTL and head and neck cancer risk.
MATERIALS AND METHODS
The study subjects included 888 non-Hispanic white subjects with newly diagnosed, We genotyped six functional TERT single nucleotide polymorphisms (SNPs) (rs2735940 G>A; rs2736098 C>T; rs2736109 G>A; rs2853669 T>C; rs2853677 A>G and rs2853690 G>A) using the TaqMan assays with the Sequence Detection Software on an ABI-Prism7900 (Applied Biosystems, Foster City, CA). These SNPs were chosen because (1) a minor allele frequency of at least 5%, (2) location in the promoter untranslated region or cording region of the gene, and (3) previous reports of an association with risk of cancers (4, 5) . Primers and probes were supplied by Applied Biosystems. For all genotypes, the assay success rate was >99% and the repeated sample's results were 100% concordant. The mean relative telomere length (RTL) was measured by SYBR Green quantitative real time PCR as previously described (7). All methods for statistical analysis have been described elsewhere as well (6) . Associations of TERT genotypes and RTL with SCCHN risk were estimated by computing the odds ratios (OR) and their 95% confidence intervals (CIs) from both univariate and multivariable logistic regression models with or without adjustment for age, sex, smoking and drinking status. To summarize published case-control association studies of TERT polymorphisms and cancer risk, we performed a meta-analysis. All statistical methods were described elsewhere for association analysis (6) and for meta-analysis (8).
RESULTS
Of the subjects, 37.9% and 49.9% of the 888 cases (aged 56.8 ± 11.3 with 74.8% male) with SCCHN were current smokers and drinkers, respectively, which were higher than that 
(15.1% and 40.8%) for the 885 cancer-free controls (aged 55.4 ± 11.0 with 74.4% male) (P <0.001 for both). The genotype frequencies of the rs2735940 G>A; rs2736098 C>T; rs2736109 G>A; rs2853669 T>C; and rs2853677 A>G SNPs were in agreement with the Hardy-Weinberg equilibrium [P = 0.663, 0.546, 0.530, 0.863, and 0.358, respectively, except for rs2853690 G>A (P = 0.003)]. Overall, no significant associations between these six TERT SNPs and SCCHN risk were observed after adjustment for age, sex, and smoking and alcohol status ( Table 1) .
We then performed a mini meta-analysis of available from published studies on the association between TERT polymorphisms and cancer risk (Figure 1) , and found that, overall, the pooled data showed that TERT functional polymorphisms were not significantly associated with cancer risk, except for the rs2736098 (OR, 1.12; 95% CI, 1.06-1.18) for 22,091 cancer cases and 78,540 controls. For RTL, carriers of shorter or longer RTL did not have altered SCCHN risk (adjusted OR = 0.97, 95% CI = 0.80-1.17), nor was any trend of associations, when RTL was categorized into quartiles (P trend = 0.618) ( Table 2) . Finally, we did not find any evidence of associations among the SNPs analyzed, RTL and SCCHN risk before or after adjustment for age, sex, smoking and drinking status (data not shown).
DISCUSSION
In this study of associations among RTL, TERT SNPs and SCCHN risk, the largest of all published case-control studies, only next to a recent breast cancer study (8), we found no evidence of associations in 888 SCCHN patients and 885 cancer-free controls in a non-Hispanic white population. This finding is consistent with our mini meta-analysis results. Our study sample size had a statistical power of 80% to detect an OR of 0.611 or 1.508 with an average TERT risk genotype of 10% or to detect a difference in RTL as small as 0.257, compared with the reported 0.9 from the only one published study of 92 head and neck cancer cases and 92 controls (2). The TERT gene has been identified as a catalytic subunit and a key regulator of telomerase activity, and over-expression of TERT is thought to be involved in the tumorigenesis of various cancers, including SCCHN. Although several association studies evaluated the role of TERT polymorphisms in cancer risk, the results are inconclusive, mostly because of small samples included in the published studies. One recent large case-control study did not find an association of TERT SNP (rs401681) with risk of cancers of the breasts, colorectum and skin, nor with telomere length (7). Telomere length in blood lymphocytes is considered a tumor marker (2, 3), but the results from association studies are also inconclusive in some cancers.
One recent prospective study of breast cancer failed to validate the findings from previous large case-control study performed by the same group (9), similarly as we found in our recent metaanalysis of 11,255 cases and 13,101 controls from 21 publications (8), namely, the case-control findings were not confirmed by prospective studies, suggesting that single larger, well-design prospective studies are warranted to confirm the reported findings.
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